# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

> **NCT06258213** · PHASE1 · COMPLETED · sponsor: **Atom Therapeutics Co., Ltd** · enrollment: 90 (actual)

## Conditions studied

- Gout
- Acute Gout Flare
- Gout Flares

## Interventions

- **DRUG:** ABP-745
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06258213
- **Lead sponsor:** Atom Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-23
- **Primary completion:** 2024-07-29
- **Final completion:** 2024-07-29
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06258213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06258213, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06258213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*